New drug zilucoplan tested for muscle weakness in french patients
NCT ID NCT06815133
First seen Jan 09, 2026 · Last updated May 17, 2026 · Updated 16 times
Summary
This study is testing a new treatment called Zilucoplan in 55 French patients with myasthenia gravis, an autoimmune disease that causes muscle weakness. The goal is to see if the drug improves muscle strength and quality of life over three months, while also checking for side effects. Participants must have a confirmed diagnosis with anti-AChR antibodies and be treated with Zilucoplan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU NICE
RECRUITINGNice, Alpes Maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.